Brain natriuretic peptide: new surrogate marker for adequacy of anti-hypertensive treatment

Mayank Shrivastava, Anoop Kumar Dhanak, Ajay Mathur, Ramji Sharma


Background: High blood pressure (hypertension) is one of the preventable causes of premature morbidity and mortality. The objective of this study was to assess the difference in mean BNP level at baseline and 3months after start of treatment among newly diagnosed hypertensive cases up to 35 years.

Methods: Study was carried out on fifty newly diagnosed hypertensive patients over a period of three months satisfying inclusion criteria. Pre and post treatment BNP level were measured and analysed.

Results: 39 (78%) cases out of 50 cases have high BNP in which 5 (10%) cases are in <30 year age group and 34 (68%) cases are in <30 year age group, High BNP level are significant in both age group with p value <0.01. 10 (20%) cases of age <30 year have normal BNP after antihypertensive treatment and 40 (80%) cases of age <30 year out of which 31 (62%) have normal BNP level and 9 (18%) cases have abnormal BNP level after antihypertensive treatment. Mean BNP level in pre antihypertensive treatment is (143.92±25.19) and post treatment is (117.26±11.20), And Mean change in BNP level pre and post treatment is (26.66±20.75) with p value <0.001which is statistically highly significant.

Conclusions: Out of many risk factors for raised BNP level, hypertension is also one of the most prevalent factors for raised BNP level. Positive correlation was found between Blood pressure and BNP level reduction after antihypertensive treatment which is highly significant. Thus Potential clinical application of BNP can be expanded, regarding monitoring the adequacy of treatment. By which we can prevent or delay the progression of disease (hypertension).


BNP, Hypertension

Full Text:



Nice guidelines, CG127, 2011. Available at Accessed on December 2016.

Theadore A. Kotchen; Harrison 18 edition; 2015:247-2042.

Murray CJ, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990-2020. In: Murray CJ, Lopez AD, eds. The Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, MA: Harvard University Press; 1996:325-395.

Mulrow PJ. Detection and control of hypertension in the population: the United States experience. Am J Hypertens. 1998;11(6 Pt 1):744-6.

Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.

The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1998;158: 573.

Chobanian AV, Bakris GL, Black HR. Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National heart, lung, and blood institute; national high blood pressure education program coordinating committee). Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-52.

Masugata H, Senda S, Inukai M, Himoto T, Hosomi N, Okada H, et al. Analysis of association between brain natriuretic peptide levels and blood pressure variability. Exp Ther Med. 2014;8(1):21-4.

Fox ER, Musani SK, Singh P, Bidulescu A et al. Association of Plasma B type natriuretic peptide concentration with longitudinal blood pressure tracking in african americans: Findings from the jackson heart study. Hypertension 2013 Jan; 61(1):48-54.

Ito H, Ishii K, Iwakura K, Nakamura F, Nagano T, Takiuchi S. Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography. Hypertens Res. 2009;32:895-900.

Anderson GH. Effect of age on hypertension. Saudi J Kidney Dis Trans. 1999;10(3):286-97.

Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J American Col Cardiol. 2002;40:976-82.

Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain Natriuretic Peptide as a risk marker for incident hyper tensive cardiovascular events.Hypertens Res. 2002;25(5)669-76.

Meno H, Inou T, Tanaka M, Tsuchiya Y, Shiqa Y, Kobayashi K, et al. Antihypertensive efficacy of the losartan/ hydrochlorthiazide combination and its effect on plasma B-type natriuretic peptide in hypertensive patients uncontrolled by Angiotensin II type-I receptor antagonist- based therapy: a multi center prospective observational study. Cli Drug Investig. 2012;32(3):171-8.

Andreadis EA, Georgiopoulos DX, Tzavara CK. Plasma brain natriuretic peptide: a biochemical marker of effective blood pressure management? J Hypertens. 2009;27:425-32.

Wei HU, Pang-HU Zhou, Xiao-Bin Zhang, Chang-Geng XU, Wei Wang. Plasma concentration of adrenomedullin and natriuretic peptides in patients with essential hypertension. Exp Ther Med. 2015;9(5):1901-8.

Cakir Z, Saritas A, Emet M, Aslan S, Akoz A, Gundogdu F. A prospective study of brain natriuretic peptide levels in three subgroups: stroke with hypertension, stroke without hypertension, and hypertension alone. Ann Indian Acad Neurol. 2010;13:47-51.